People
Verseon has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform. Financial terms were not disclosed.
The Biotechnology Innovation Organization, Passage Bio and Palisade Bio saw leadership shakeups at the top, while Maze Therapeutics, Cerecin and more appointed new chief medical officers.
Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to advance its portfolio of immunomodulators and oncology therapies.
The internet and “common wisdom” aren’t always right. Here are some of the top myths about three common conditions, and the truth from leading experts in their fields.
Biotechnology Innovation Organization, the world’s largest science and public advocacy organization, announced Monday it has tapped Rachel King to serve as interim President and CEO.
Biogen may have found its CEO in Mathai Mammen - former head of research and development in pharmaceuticals at Johnson & Johnson.
Movers & Shakers: New C-Suites for Assembly Biosciences, Urica Therapeutics, BlueSphere Bio and More
Life sciences and biopharma companies added new CEOs, CMOs and CSOs to guide their companies into the future and oversee developmental programs.
With ambitions to enter the clinic in the first half of 2023, Keir Loiacono, esq., aims to double down on BlueSphere’s strengths rather than make any major course corrections.
As it gears up to launch several new products, Moderna has created a new leadership role and onboarded an industry veteran.
Life science companies made adjustments to their leadership teams with multiple appointments for chief commercial officers, chief business officers and more in this week’s Movers & Shakers.
PRESS RELEASES